Cargando…
Multilevel pharmacokinetics-driven modeling of metabolomics data
INTRODUCTION: Multilevel modeling is a quantitative statistical method to investigate variability and relationships between variables of interest, taking into account population structure and dependencies. It can be used for prediction, data reduction and causal inference from experiments and observ...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306155/ https://www.ncbi.nlm.nih.gov/pubmed/28255294 http://dx.doi.org/10.1007/s11306-017-1164-4 |
_version_ | 1782507140505665536 |
---|---|
author | Daghir-Wojtkowiak, Emilia Wiczling, Paweł Waszczuk-Jankowska, Małgorzata Kaliszan, Roman Markuszewski, Michał Jan |
author_facet | Daghir-Wojtkowiak, Emilia Wiczling, Paweł Waszczuk-Jankowska, Małgorzata Kaliszan, Roman Markuszewski, Michał Jan |
author_sort | Daghir-Wojtkowiak, Emilia |
collection | PubMed |
description | INTRODUCTION: Multilevel modeling is a quantitative statistical method to investigate variability and relationships between variables of interest, taking into account population structure and dependencies. It can be used for prediction, data reduction and causal inference from experiments and observational studies allowing for more efficient elucidation of knowledge. OBJECTIVES: In this study we introduced the concept of multilevel pharmacokinetics (PK)-driven modelling for large-sample, unbalanced and unadjusted metabolomics data comprising nucleoside and creatinine concentration measurements in urine of healthy and cancer patients. METHODS: A Bayesian multilevel model was proposed to describe the nucleoside and creatinine concentration ratio considering age, sex and health status as covariates. The predictive performance of the proposed model was summarized via area under the ROC, sensitivity and specificity using external validation. RESULTS: Cancer was associated with an increase in methylthioadenosine/creatinine excretion rate by a factor of 1.42 (1.09–2.03) which constituted the highest increase among all nucleosides. Age influenced nucleosides/creatinine excretion rates for all nucleosides in the same direction which was likely caused by a decrease in creatinine clearance with age. There was a small evidence of sex-related differences for methylthioadenosine. The individual a posteriori prediction of patient classification as area under the ROC with 5th and 95th percentile was 0.57(0.5–0.67) with sensitivity and specificity of 0.59(0.42–0.76) and 0.57(0.45–0.7), respectively suggesting limited usefulness of 13 nucleosides/creatinine urine concentration measurements in predicting disease in this population. CONCLUSION: Bayesian multilevel pharmacokinetics-driven modeling in metabolomics may be useful in understanding the data and may constitute a new tool for searching towards potential candidates of disease indicators. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11306-017-1164-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5306155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-53061552017-02-28 Multilevel pharmacokinetics-driven modeling of metabolomics data Daghir-Wojtkowiak, Emilia Wiczling, Paweł Waszczuk-Jankowska, Małgorzata Kaliszan, Roman Markuszewski, Michał Jan Metabolomics Original Article INTRODUCTION: Multilevel modeling is a quantitative statistical method to investigate variability and relationships between variables of interest, taking into account population structure and dependencies. It can be used for prediction, data reduction and causal inference from experiments and observational studies allowing for more efficient elucidation of knowledge. OBJECTIVES: In this study we introduced the concept of multilevel pharmacokinetics (PK)-driven modelling for large-sample, unbalanced and unadjusted metabolomics data comprising nucleoside and creatinine concentration measurements in urine of healthy and cancer patients. METHODS: A Bayesian multilevel model was proposed to describe the nucleoside and creatinine concentration ratio considering age, sex and health status as covariates. The predictive performance of the proposed model was summarized via area under the ROC, sensitivity and specificity using external validation. RESULTS: Cancer was associated with an increase in methylthioadenosine/creatinine excretion rate by a factor of 1.42 (1.09–2.03) which constituted the highest increase among all nucleosides. Age influenced nucleosides/creatinine excretion rates for all nucleosides in the same direction which was likely caused by a decrease in creatinine clearance with age. There was a small evidence of sex-related differences for methylthioadenosine. The individual a posteriori prediction of patient classification as area under the ROC with 5th and 95th percentile was 0.57(0.5–0.67) with sensitivity and specificity of 0.59(0.42–0.76) and 0.57(0.45–0.7), respectively suggesting limited usefulness of 13 nucleosides/creatinine urine concentration measurements in predicting disease in this population. CONCLUSION: Bayesian multilevel pharmacokinetics-driven modeling in metabolomics may be useful in understanding the data and may constitute a new tool for searching towards potential candidates of disease indicators. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11306-017-1164-4) contains supplementary material, which is available to authorized users. Springer US 2017-02-08 2017 /pmc/articles/PMC5306155/ /pubmed/28255294 http://dx.doi.org/10.1007/s11306-017-1164-4 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Daghir-Wojtkowiak, Emilia Wiczling, Paweł Waszczuk-Jankowska, Małgorzata Kaliszan, Roman Markuszewski, Michał Jan Multilevel pharmacokinetics-driven modeling of metabolomics data |
title | Multilevel pharmacokinetics-driven modeling of metabolomics data |
title_full | Multilevel pharmacokinetics-driven modeling of metabolomics data |
title_fullStr | Multilevel pharmacokinetics-driven modeling of metabolomics data |
title_full_unstemmed | Multilevel pharmacokinetics-driven modeling of metabolomics data |
title_short | Multilevel pharmacokinetics-driven modeling of metabolomics data |
title_sort | multilevel pharmacokinetics-driven modeling of metabolomics data |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306155/ https://www.ncbi.nlm.nih.gov/pubmed/28255294 http://dx.doi.org/10.1007/s11306-017-1164-4 |
work_keys_str_mv | AT daghirwojtkowiakemilia multilevelpharmacokineticsdrivenmodelingofmetabolomicsdata AT wiczlingpaweł multilevelpharmacokineticsdrivenmodelingofmetabolomicsdata AT waszczukjankowskamałgorzata multilevelpharmacokineticsdrivenmodelingofmetabolomicsdata AT kaliszanroman multilevelpharmacokineticsdrivenmodelingofmetabolomicsdata AT markuszewskimichałjan multilevelpharmacokineticsdrivenmodelingofmetabolomicsdata |